Johnson & Johnson
USUSDJohnson & Johnson (XETRA:JNJ) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- jnj.com
- Investor Relations
- investor.jnj.com/overview/default.aspx
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- New Brunswick, United States
- CEO
- Joaquin Duato
- Mitarbeiter
- 136 400
- Gegründet
- 1886
- Ausstehende Aktien
- Streubesitz
- 2.41 Mrd.
- Marktkapitalisierung
- 655.37 Mrd. USD
- Insider
- 0.05%
- Institutionelle Anleger
- 76.73%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- XSNP
- ISIN
- US4781601046
- LEI
- 549300G0CFPGEF6X2043
- P/E
- 31.7
- Ausschüttungsquote
- 60.0%
- FCF
- 22.2 Mrd. USD
- Ausschüttung / FCF
- 57%
- Schulden
- 49.0 Mrd. USD1.3 J. FCF
- Dividendenserie
- 56+ J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 28.06.2026 (letzter Bericht des Unternehmens).
- NAV
Beschreibung
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Dividenden
Johnson & Johnson (JNJ) zahlt vierteljährlich Dividenden. Pro Jahr (12 Monate bis einschließlich der zuletzt angekündigten Zahlung): 5.32 USD pro Aktie (Zahlungen: 4). Das entspricht etwa 2.08% des aktuellen Aktienkurses. Der nächste Ex-Dividenden-Tag ist der 24.11.2026: 1.34 USD pro Aktie, Zahlung am 08.12.2026. Ununterbrochene Dividendengeschichte: 56 Jahre.
| Ex-tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-11-24 angekündigt | 2026-12-08 | 1.3400 USD | 0.5/2.1 % | vierteljährlich | US:JNJ |
| 2026-08-25 | 2026-09-08 | 1.3400 USD | 0.5/1.9 % | vierteljährlich | US:JNJ |
| 2026-05-26 | 2026-06-09 | 1.3400 USD | 0.6/2.2 % | vierteljährlich | US:JNJ |
| 2026-02-24 | 2026-03-10 | 1.3000 USD | 0.5/2.1 % | vierteljährlich | US:JNJ |
| 2025-11-25 | 2025-12-09 | 1.3000 USD | 0.6/2.5 % | vierteljährlich | US:JNJ |
| 2025-08-26 | 2025-09-09 | 1.3000 USD | 0.7/2.8 % | vierteljährlich | US:JNJ |
| 2025-05-27 | 2025-06-10 | 1.3000 USD | 0.9/3.3 % | vierteljährlich | US:JNJ |
| 2025-02-18 | 2025-03-04 | 1.2400 USD | 0.8/3.2 % | vierteljährlich | US:JNJ |
| 2024-11-26 | 2024-12-10 | 1.2400 USD | 0.8/3.2 % | vierteljährlich | US:JNJ |
| 2024-08-27 | 2024-09-10 | 1.2400 USD | 0.5/1.9 % | vierteljährlich | US:JNJ |
| 2024-05-20 | 2024-06-04 | 1.2400 USD | 0.5/1.9 % | vierteljährlich | US:JNJ |
| 2024-02-16 | 2024-03-05 | 1.1900 USD | 0.5/1.9 % | vierteljährlich | US:JNJ |
| 2023-11-20 | 2023-12-05 | 1.1900 USD | 0.5/1.8 % | vierteljährlich | US:JNJ |
| 2023-08-25 | 2023-09-07 | 1.1900 USD | 0.5/1.8 % | vierteljährlich | US:JNJ |
| 2023-05-22 | 2023-06-06 | 1.1900 USD | 0.5/1.8 % | vierteljährlich | US:JNJ |
| 2023-02-17 | 2023-03-07 | 1.1300 USD | 0.4/1.8 % | vierteljährlich | US:JNJ |
| 2022-11-21 | 2022-12-06 | 1.1300 USD | 0.4/1.7 % | vierteljährlich | US:JNJ |
| 2022-08-22 | 2022-09-06 | 1.1300 USD | 0.4/1.7 % | vierteljährlich | US:JNJ |
| 2022-05-23 | 2022-06-07 | 1.1300 USD | 0.4/1.3 % | vierteljährlich | US:JNJ |
| 2022-02-18 | 2022-03-08 | 1.0600 USD | 0.4/0.8 % | vierteljährlich | US:JNJ |
| 2021-11-22 | 2021-12-07 | 1.0600 USD | 0.4/0.4 % | vierteljährlich | US:JNJ |
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| BlackRock | 8.8% | 212.1 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 157.23 Mio. | 2026-06-30 |
| State Street Corporation | 5.55% | 133.78 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 76.42 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.67% | 64.37 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 62.38 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.45% | 59.09 Mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.42% | 58.3 Mio. | 2026-06-30 |
| Morgan Stanley | 1.86% | 44.81 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 32.48 Mio. | 2026-07-31 |
| NORGES BANK | 1.32% | 31.83 Mio. | 2026-06-30 |
| State Farm Mutual Automo… | 1.31% | 31.59 Mio. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 31.13 Mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 29.45 Mio. | 2026-08-31 |
| Northern Trust Corporati… | 1.19% | 28.79 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 22.91 Mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 17.3 Mio. | 2026-08-31 |
| VANGUARD SPECIALIZED FUN… | 0.56% | 13.53 Mio. | 2026-04-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 13.07 Mio. | 2026-06-30 |
| VANGUARD WHITEHALL FUNDS… | 0.39% | 9.48 Mio. | 2026-04-30 |
| DUATO JOAQUIN BOIX (Chie… | ≈0.01% | 307 837 | 2026-08-13 |
| TAUBERT JENNIFER L (Offi… | ≈0.01% | 194 451 | 2026-08-17 |
| WENGEL KATHRYN E (Chief… | ≈0% | 114 659 | 2026-06-11 |
| WOLK JOSEPH J (Chief Fin… | ≈0% | 85 008 | 2026-02-17 |
| SCHMID TIMOTHY (Officer) | ≈0% | 26 251 | 2026-09-02 |
| SWANSON JAMES D (Chief T… | ≈0% | 25 698 | 2026-02-17 |
| REED JOHN C (Officer) | ≈0% | 24 911 | 2026-05-01 |
| DECKER ROBERT J (Officer… | ≈0% | 24 462 | 2026-02-27 |
| BROADHURST VANESSA (Offi… | ≈0% | 23 003 | 2026-07-20 |
| MULHOLLAND KRISTEN (Offi… | ≈0% | 19 830 | 2026-02-13 |
| The Vanguard Group | — | — | — |
